Cas:56442-19-4 4-[(4-Methylbenzyl)oxy]benzenecarboxylic acid manufacturer & supplier

Chemical Name:4-[(4-Methylbenzyl)oxy]benzenecarboxylic acid

CAS.NO:56442-19-4

Synonyms:4-(4-Methyl-benzyloxy)-benzoesaeure;p-(4′-Methylbenzyloxy)benzoesaeure;4-[(4-methylbenzyl)oxy]benzoic acid

Molecular Formula:C₁₅H₁₄O₃

Molecular Weight:242.27000

HS Code:2918990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:409.2ºC at 760mmHg

Density:1.193g/cm3

Index of Refraction:

PSA:46.53000

Exact Mass:242.09400

LogP:3.27220

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(4-Methyl-benzyloxy)-benzoesaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[(4-methylbenzyl)oxy]benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[(4-methylbenzyl)oxy]benzoic acid Use and application,4-[(4-methylbenzyl)oxy]benzoic acid technical grade,usp/ep/jp grade.

Related News: Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. 4-[(4-Methylbenzyl)oxy]benzenecarboxylic acid manufacturer Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 4-[(4-Methylbenzyl)oxy]benzenecarboxylic acid supplier Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. 4-[(4-Methylbenzyl)oxy]benzenecarboxylic acid vendor Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations. 4-[(4-Methylbenzyl)oxy]benzenecarboxylic acid factory Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process.